Mislang, A., Mollard, R., Tapia Rico G., Fairlie, D., Lee, E.F., Harris, T.J., Aston, R. & Brown, M. P. (2020). A preliminary assessment of oral monepantel’s tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors. Cancer Chemother Pharmacol 86, 589-594, doi:10.1007/s00280-020-04146-5.


Ataie-Kachoie, P., Pillai, K., Badar, S., Akhter, J. & Morris, D. L. (2018). Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies. American journal of cancer research 8, 2064-2075.


Bahrami, F., Morris, D. L., Rufener, L., & Pourgholami, M. H. (2014a). Anticancer properties of novel aminoacetonitrile derivative monepantel (ADD 1566) in pre-clinical models of human ovarian cancer. American Journal of Cancer Research, 4(5), 545–557.


Bahrami, F., Pourgholami, M. H., Mekkawy, A. H., Rufener, L., & Morris, D. L. (2014b). Monepantel induces autophagy in human ovarian cancer cells through disruption of the mTOR/p70S6K signalling pathway. American Journal of Cancer Research, 4(5), 558–571.


Lecová, L., Stuchlíková, L., Prchal, L., & Skálová, L. (2014). Monepantel: the most studied new anthelmintic drug of recent years. Parasitology, 141(13), 1686–1698.

Learn More